Evidence map›Paper›PMID 39843851›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2025

Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study.

Ryan Terry-Lorenzo, Daniel Albrecht, Sabrinia Crouch, Richard Wong, Gordon Loewen, Nagdeep Giri, Heather Skor, Kelly Lin, Christine M Sandiego, Meghan Pajonas and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Ryan Terry-LorenzoNeurocrine Biosciences, Inc., San Diego, CA, USA. rlorenzo@neurocrine.com.ORCID http://orcid.org/0009-0004-6170-8990
Daniel AlbrechtNeurocrine Biosciences, Inc., San Diego, CA, USA.
Sabrinia CrouchNeurocrine Biosciences, Inc., San Diego, CA, USA.
Richard WongNeurocrine Biosciences, Inc., San Diego, CA, USA.
Gordon LoewenNeurocrine Biosciences, Inc., San Diego, CA, USA.
Nagdeep GiriNeurocrine Biosciences, Inc., San Diego, CA, USA.
Heather SkorNeurocrine Biosciences, Inc., San Diego, CA, USA.
Kelly LinNeurocrine Biosciences, Inc., San Diego, CA, USA.
Christine M SandiegoInvicro, LCC., Needham, MA, USA.
Meghan PajonasInvicro, LCC., Needham, MA, USA.
Eugenii A RabinerInvicro, LCC., Needham, MA, USA.ORCID http://orcid.org/0000-0003-3612-6687
Roger N GunnInvicro, LCC., Needham, MA, USA.
David S RussellInvicro, LCC., Needham, MA, USA.ORCID http://orcid.org/0000-0002-9105-2943
Dietrich HaubenbergerNeurocrine Biosciences, Inc., San Diego, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39843851
PMCPMC11845734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.